EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

WHO guidelines on biosimilars: Toward improved access to safe and effective products

Hye-Na Kang, Meenu Wadhwa, Ivana Knezevic, Clive Ondari, Mariangela Simao

Annals of the New York Academy of Sciences · 2023-03 · 1521 (1) · 96-103

DOI: 10.1111/nyas.14965 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Annals of the New York Academy of Sciences, online erschienen am 24.01.2023. Verfasst von Hye-Na Kang und 4 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The World Health Assembly resolution on access to biotherapeutics in 2014 urges WHO and Member States to facilitate access to biotherapeutics while ensuring their quality, safety, and efficacy. While efforts to date have contributed to increased availability and better access to biotherapeutics, including biosimilars, huge gaps still remain, with lack of product access identified as a problem in many countries. A thorough review of the WHO guidelines on biosimilars issued in 2009 in view of technical developments, accumulated and emerging scientific evidence as well as experience in biosimilar evaluation since the release of the guidelines provided an opportunity to introduce greater flexibility and to reduce regulatory requirements in biosimilar development where possible. Based on the identification, draft revisions of the WHO guidelines were prepared with input from extensive consultation with various stakeholders and the broader public. The move toward a greater emphasis on quality and functional in vitro assessment enables the reduction of cost and timelines of development and supports streamlined regulatory approval as a first critical step toward product availability. This article includes the key updates that have been incorporated in the revised guidelines but are not restricted to these alone and should be read in conjunction with the guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHumansWorld Health OrganizationDrug Approval

Stichwörter der Autor:innen

WHOaccessbiosimilarregulatory guidelinesrevision

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland.
  • Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, UK.

Förderung

  • World Health Organization

Zitieren

APA

Kang, H. N., Wadhwa, M., Knezevic, I., Ondari, C., & Simao, M. (2023). WHO guidelines on biosimilars: Toward improved access to safe and effective products. Annals of the New York Academy of Sciences, 1521(1), 96-103. https://doi.org/10.1111/nyas.14965

Vancouver

Kang HN, Wadhwa M, Knezevic I, Ondari C, Simao M. WHO guidelines on biosimilars: Toward improved access to safe and effective products. Annals of the New York Academy of Sciences. 2023;1521(1):96-103. doi:10.1111/nyas.14965

BibTeX
@article{Kang2023,
  author = {Kang, Hye-Na and Wadhwa, Meenu and Knezevic, Ivana and Ondari, Clive and Simao, Mariangela},
  title = {WHO guidelines on biosimilars: Toward improved access to safe and effective products},
  journal = {Annals of the New York Academy of Sciences},
  year = {2023},
  volume = {1521},
  number = {1},
  pages = {96--103},
  doi = {10.1111/nyas.14965}
}
Kostenlos starten →